MEIRAGTX HLDGSDL-,0000388

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy» Mehr auf globenewswire.com

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.77 per share a year ago.» Mehr auf zacks.com

-  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson's disease -  Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BLA filing   -  Efficacy data of rAAV8.hRKp.AIPL1 for the treatment of AIPL1-related retinal dystrophy, or LCA4, published in The Lancet, demonstrating meaningful responses in 11 out of 11 LCA4 children treated. Filing for Marketing Authorization Approval (MAA) under exceptional circumstances with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and in discussions with the FDA around a potentially similar pathway to approval in the US LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2025, and provided a corporate update.» Mehr auf globenewswire.com